Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn

Dr Aisling O'Leary

Dr Aisling O'Leary BSc (Pharm), PhD, MPSI
Lecturer in Pharmacy Practice
Tel: +353 1 402 2786

Dr. O'Leary, a graduate of Dublin University, Trinity College Dublin with a Ph.D in pharmaceutical chemistry, is a lecturer in Pharmacy Practice lecturing on clinical research methodologies, critical appraisal skills, pharmacoeconomics and clinical therapeutics. She is the Module Co-Ordinator for a number of modules of the MPharm programme. She is also Chief II Pharmacist in the National Centre for Pharmacoeconomics based in St. James' Hospital (, where she evaluates the cost-effectiveness of new medicines and undertakes research into post health technology assessment initiatives.

Professional Committees
Member of the Pharmaceutical Society of Ireland
Member of the Irish Medication Safety Network
Member of the Hospital Pharmacists Association of Ireland
Member of the National Pharmacy Reference Group (PSI)
Member of the Hospital Pharmacy Assessment Group 2012 (PSI)

Research Interests
Pharmacoepidemiological studies in primary care pharmacy
Pharmacoeconomics and cost-effectiveness of new technologies
Observational outcomes research - post-HTA (Hepatitis C)
Medication safety issues
Medicines information in primary care
Audit in hospital pharmacy practice

1. Fontela C, Castilla J, Juanbeltz R, Martínez-Baz I, Rivero M, O'Leary A, Larrea N & San Miguel R: Comorbidities and cardiovascular risk factors in an aged cohort of HIV-infected patients on antiretroviral treatment in a Spanish hospital in 2016. EP
ub 2018 March 12. DOI: 10.1080/00325481.2018.1446653

2. Mar J, Martínez-Baz I, Ibarrondo O, Juanbeltz R, San Miguel R, Casado I, O'Leary A, Castilla J.
Expert Rev Gastroenterol Hepatol. 2017 Sep 26. doi: 10.1080/17474124.2017.1383155. [Epub ahead of print].

3. Gray E, Norris S, Schmitz S, 
O'Leary A. Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes? J Comp Eff Res. 2016 Nov 17. [Epub ahead of print].

4. Ní Cheallaigh C, 
O'Leary A, Keating S, Singeton A, Heffernan S, Keenan E, Robson L, Sears J, Moloney J, Arora S, Bergin C, Norris S. Telementoring with project ECHO: a pilot study in Europe. BMJ Innovations Publish Ahead of Print, published on August 24, 2017 as doi:10.1136/bmjinnov-2016-000141.

5. LT Nguyen, E Gray, 
A O'Leary, M Carr, CF De Gascun. The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors. 2016. PloS one 11 (10), e0163900.

6. V Gimeno-Ballester, J Mar, 
A O'Leary, R Adams, R San Miguel. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. 2016. Expert Review of Gastroenterology & Hepatology, 1-9.

7. Gray, E., 
O'Leary, A., Stewart, S., Bergin, C., Cannon, M., Courtney, G., Crosbie, O., De Gascun, C.F., Feeney, E., Houlihan, D.D., Kelleher, B., Lambert, J.S., Lee, J., Mallon, P., McConkey, S., McCormick, A., McKiernan, S., McNally, C., Murray, F., Sheehan, G., Norris, S., Fanning, L.J., on behalf of the Irish Hepatitis C Outcomes and Research Network (ICORN), High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme, Journal of Hepatology (2016), doi:

8. Gray E, 
O'Leary A, Kieran JA, Fogarty E, Dowling T, Norris S; Irish Hepatitis C Outcomes and Research Network (ICORN). Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection. J Viral Hepat. 2016 Mar 21. doi: 10.1111/jvh.12532. [Epub ahead of print] PubMed PMID: 26996144.

O'Leary A, Usher C, Lynch M, Hall M, Hemeryk L, Spillane S, Gallagher P, Barry M. Generic medicines and generic substitution: contrasting perspectives of stakeholders in Ireland. BMC Res Notes. 2015 Dec 15;8:790. doi: 10.1186/s13104-015-1764-x. PubMed PMID: 26670010; PubMed Central PMCID: PMC4678461.

10. Gray E, Leahy J, 
O'Leary A, Norris S, Walsh C. Estimation of The Relative Efficacy of Licensed Regimens for Genotype-1 Hcv Infection Using A Mixed Treatment Comparison. Value Health. 2015 Nov;18(7):A577. doi: 10.1016/j.jval.2015.09.1921. Epub 2015 Oct 20. PubMed PMID: 26533243.

11. Kieran JA, Norris S, 
O'Leary A, Walsh C, Merriman R, Houlihan D, McCormick PA, McKiernan S, Bergin C, Barry M. Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study. BMC Infect Dis. 2015 Oct 26;15:471. doi: 10.1186/s12879-015-1208-1. PubMed PMID: 26503519; PubMed Central PMCID: PMC4624167.

12. Nguyen LT, Gray E, Dean J, Carr M, Connell J, De Gascun C, Nguyen LA, 
O'Leary A, Bergin C, Hall W, Norris S. Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals. Antivir Ther. 2015;20(8):865-9. doi: 10.3851/IMP2964. Epub 2015 Apr 29. PubMed PMID: 25920764.

13. Brennan A, Morley D, 
O'Leary A, Bergin CJ, Horgan M. Determinants of HIV outpatient service utilization: a systematic review. AIDS Behav. 2015 Jan;19(1):104-19. doi: 10.1007/s10461-014-0814-z. Review. PubMed PMID: 24907780.

14. Kieran JA, Schmitz S, 
O'Leary A, Walsh C, Bergin C, Norris S, Barry MG. Reply to Calcagno et al. Clin Infect Dis. 2013 Jun;56(11):1678-9. doi: 10.1093/cid/cit092. Epub 2013 Feb 15. PubMed PMID: 23418277.

15. Kieran J, Schmitz S, 
O'Leary A, Walsh C, Bergin C, Norris S, Barry M. The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clin Infect Dis. 2013 Jan;56(2):228-35. doi: 10.1093/cid/cis880. Epub 2012 Oct 16. Review. PubMed PMID: 23074309.

O'Leary A, Grimes T, Gallagher P and Interns and Tutors of the National Pharmacy Internship Programme 2009-2010. Collaborative research across community pharmacy in Ireland facilitated through the national pharmacy internship programme. Pharmacoepidemiology and Drug Safety 2011; 20: S1-S14.

17. Tilson L, 
O'Leary A, Usher C, Barry M. Pharmacoeconomic evaluation in Ireland: a review of the process. Pharmacoeconomics. 2010;28(4):307-22. doi:10.2165/11318790-000000000-00000. PubMed PMID: 20222754.

18. Nolan DP, O'Connor MB, O'Connor C, Moriarty M, 
O'Leary A, Bergin C. HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies. Int J STD AIDS. 2010 Jan;21(1):75-6. doi:10.1258/ijsa.2009.009364. Epub 2009 Nov 2. PubMed PMID: 19884356.

O'Leary A, Breen D, Casey E.B. Steroid-Induced Psychosis - two case reports. Irish Pharmacy Journal 2001 (July): 298-300.

20. Keating S, 
O'Leary A, Bergin C, Kane D, Mulcahy F. Malignant Neuroleptic Syndrome: Four Cases in the Irish AIDS Population. (Letter) Int.J.Std.AIDS 1996 Aug-Sep; 7(5): 380-382.

21. Bergin C, 
O'Leary A, McCreary C, Sabra K, Mulcahy F. Treatment of Kaposi's sarcoma with Liposomal doxorubicin. Am. J Health-Syst Pharm. 1995; 52: 2001-2004.